Francis J Burrows Selected Research

apricoxib

9/2012	Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.
9/2012	Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Francis J Burrows Research Topics

Disease

16	Neoplasms (Cancer) 12/2021 - 01/2002
3	Pancreatic Neoplasms (Pancreatic Cancer) 12/2021 - 09/2012
3	Glioma (Gliomas) 09/2016 - 01/2002
3	Multiple Myeloma 09/2016 - 05/2013
2	Neoplasm Metastasis (Metastasis) 01/2019 - 09/2012
2	Leukemia 05/2013 - 10/2005
2	Colorectal Neoplasms (Colorectal Cancer) 09/2012 - 01/2002
1	Adenocarcinoma 01/2019
1	Hypoxia (Hypoxemia) 01/2019
1	Brain Neoplasms (Brain Tumor) 01/2016
1	Glioblastoma (Glioblastoma Multiforme) 01/2016
1	Breast Neoplasms (Breast Cancer) 11/2014
1	Carcinoma (Carcinomatosis) 09/2012
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2012
1	Hodgkin Disease (Hodgkin's Disease) 08/2009
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 12/2006
1	Colonic Neoplasms (Colon Cancer) 08/2006
1	Neuroblastoma 05/2006
1	Stomach Neoplasms (Stomach Cancer) 01/2006
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2005
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2004
1	Melanoma (Melanoma, Malignant) 01/2002

Drug/Important Bio-Agent (IBA)

6	Proteins (Proteins, Gene)FDA Link 05/2013 - 06/2004
6	Heat-Shock Proteins (Heat-Shock Protein)IBA 08/2009 - 06/2004
3	Pharmaceutical PreparationsIBA 12/2021 - 10/2004
3	Molecular Chaperones (Chaperone, Molecular)IBA 08/2009 - 06/2004
3	tanespimycin (17AAG)IBA 12/2006 - 09/2003
2	Proteasome InhibitorsIBA 09/2016 - 01/2016
2	marizomibIBA 09/2016 - 01/2016
2	Proteasome Endopeptidase Complex (Proteasome)IBA 09/2016 - 01/2016
2	Bortezomib (Velcade)FDA Link 01/2016 - 05/2013
2	Phosphotransferases (Kinase)IBA 11/2014 - 10/2004
2	Gemcitabine FDA Link 09/2012 - 08/2009
2	apricoxibIBA 09/2012 - 09/2012
2	6- chloro- 9- (4- methoxy- 3,5- dimethylpyridin- 2- ylmethyl)- 9H- purin- 2- ylamineIBA 08/2009 - 04/2009
2	Oncogene Proteins (Oncogene Protein)IBA 04/2009 - 10/2004
2	geldanamycinIBA 12/2006 - 05/2006
1	Chemokine CXCL12IBA 12/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019
1	CollagenIBA 01/2019
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2019
1	carfilzomibIBA 01/2016
1	Mitogen-Activated Protein Kinase 7IBA 11/2014
1	Lenalidomide (CC 5013)FDA Link 05/2013
1	14- methyl- 20- oxa- 5,7,14,26- tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8(27),9,11,16,21,23- decaeneIBA 05/2013
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 09/2012
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2012
1	Dihydrotachysterol (AT 10)IBA 09/2012
1	Antineoplastic Agents (Antineoplastics)IBA 09/2012
1	LigandsIBA 08/2009
1	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2009
1	Annexin A5IBA 08/2009
1	NF-kappa B (NF-kB)IBA 08/2009
1	Natural Killer Cell ReceptorsIBA 08/2009
1	Biomarkers (Surrogate Marker)IBA 04/2009
1	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 04/2009
1	AminesIBA 01/2006
1	SaltsIBA 01/2006
1	Imatinib Mesylate (Gleevec)FDA Link 10/2004
1	Biological ProductsIBA 10/2004
1	DNA (Deoxyribonucleic Acid)IBA 10/2004
1	Coloring Agents (Dyes)IBA 01/2002
1	Antiviral Agents (Antivirals)IBA 01/2002
1	Ganciclovir (Cytovene)FDA LinkGeneric 01/2002
1	Thymidine KinaseIBA 01/2002

Therapy/Procedure

5	Therapeutics 12/2021 - 09/2003
2	Oral Administration 04/2009 - 08/2006
1	Drug Therapy (Chemotherapy) 05/2006
1	Aftercare (After-Treatment) 01/2002